The 3 analysts offering 12-month price forecasts for Cellectar Biosciences Inc have a median target of 5.50, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +657.58% increase from the last price of 0.73.
The current consensus among 3 polled investment analysts is to Buy stock in Cellectar Biosciences Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.10
Reporting Date Mar 15
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.